Patient reported outcomes following initiation of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in a specialist endocrinology practice of the LMC Diabetes Registry: The PROGRESS-Diabetes Study
Diabetes Research and Clinical Practice Aug 26, 2019
Brown RE, Abitbol A, Bajaj HS, et al. - In patients who started dulaglutide or liraglutide as part of usual clinical therapy, researchers conducted this observational study to compare patient-reported outcomes and clinical results. Between April 2017 and January 2018, adults with T2D who started dulaglutide or liraglutide were recruited. Using propensity score matching, clinical outcomes were evaluated in a post-hoc retrospective analysis. In real-world specialist practice, patients who started dulaglutide or liraglutide had comparable improvements in the satisfaction of diabetes medication and the satisfaction of the diabetes device. Important improvements in medication adherence scores were only seen in patients with dulaglutide. Comparable patterns of change in A1C were seen in both cohorts of treatment; liraglutide had significantly higher weight loss, like clinical trial findings.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries